Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020)
Attributed to:
nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)32466-1
PubMed Identifier: 33220855
Publication URI: http://europepmc.org/abstract/MED/33220855
Type: Journal Article/Review
Parent Publication: The Lancet
Issue: 10267
ISSN: 0140-6736